
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) obtained FDA's approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, previously denoted as AMP-008, for treating or preventing bronchospasm in patients aged four and above with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in the same age group. The FDA affirmed the bioequivalence and therapeutic equivalence of Amphastar's albuterol to Teva Respiratory LLC's ProAir® HFA (albuterol sulfate) Inhalation Aerosol. Amphastar's CEO and President highlighted the company's technological and manufacturing capabilities and the commitment to quality.
Like
Save
Share